CYP7A1 and steatosis: Consequently, the recovery of normal CYP7A1 levels in the TX mice under TDMQ20 treatment is consistent with both the reduction in steatosis in the liver and the activation of bile excretion of Cu that we recently reported in TX mice treated with TDMQ20 [8].